DE69924735D1 - Zur wirkstoffabgabe an zielorten im darm fähige zubereitung - Google Patents

Zur wirkstoffabgabe an zielorten im darm fähige zubereitung

Info

Publication number
DE69924735D1
DE69924735D1 DE69924735T DE69924735T DE69924735D1 DE 69924735 D1 DE69924735 D1 DE 69924735D1 DE 69924735 T DE69924735 T DE 69924735T DE 69924735 T DE69924735 T DE 69924735T DE 69924735 D1 DE69924735 D1 DE 69924735D1
Authority
DE
Germany
Prior art keywords
intestine
medicinal substance
site
preparation
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69924735T
Other languages
English (en)
Other versions
DE69924735T2 (de
Inventor
Takashi Ishibashi
Hiroaki Kubo
Hiroyuki Yoshino
Masakazu Mizobe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Seiyaku Co Ltd
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Application granted granted Critical
Publication of DE69924735D1 publication Critical patent/DE69924735D1/de
Publication of DE69924735T2 publication Critical patent/DE69924735T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69924735T 1998-07-28 1999-07-26 Zur wirkstoffabgabe an zielorten im darm fähige zubereitung Expired - Lifetime DE69924735T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP21167898 1998-07-28
JP21167898 1998-07-28
PCT/JP1999/003989 WO2000006128A1 (fr) 1998-07-28 1999-07-26 Preparation capable de liberer un medicament au niveau d'un site cible dans l'intestin

Publications (2)

Publication Number Publication Date
DE69924735D1 true DE69924735D1 (de) 2005-05-19
DE69924735T2 DE69924735T2 (de) 2006-01-19

Family

ID=16609788

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69924735T Expired - Lifetime DE69924735T2 (de) 1998-07-28 1999-07-26 Zur wirkstoffabgabe an zielorten im darm fähige zubereitung

Country Status (9)

Country Link
US (1) US6638534B1 (de)
EP (1) EP1101490B1 (de)
KR (1) KR100501022B1 (de)
CN (1) CN1163223C (de)
AT (1) ATE292961T1 (de)
AU (1) AU4800999A (de)
CA (1) CA2338780C (de)
DE (1) DE69924735T2 (de)
WO (1) WO2000006128A1 (de)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432448B1 (en) * 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
IL155959A0 (en) 2000-11-28 2003-12-23 Fmc Corp Edible pga (propylene glycol alginate) coating composition
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US7906145B2 (en) 2002-04-09 2011-03-15 Flamel Technologies Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
AU2003246791A1 (en) 2002-04-09 2003-10-20 Flamel Technologies Oral suspension of amoxicillin capsules
US20030220351A1 (en) * 2002-05-24 2003-11-27 Gilbert Gonzales Enteric coated caffeine tablet
EP1607087A1 (de) * 2003-03-27 2005-12-21 Hisamitsu Pharmaceutical Co., Inc. Medizinische, oral einzunehmende präparate zur abgabe im dickdarm, medizinische, oral einzunehmende präparate zur behandlung von dickdarmkrebs und medizinische, oral einzunehmende präparate zur behandlung von dickdarmentzündung
US7737133B2 (en) * 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
WO2005046684A1 (en) 2003-11-04 2005-05-26 Shire Laboratories, Inc. Once daily dosage forms of trospium
CA2536401C (en) 2003-11-04 2011-08-30 Shire Laboratories Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
CA2547137A1 (en) 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
WO2005074598A2 (en) 2004-01-30 2005-08-18 Johns Hopkins University Nitroxyl progenitor compounds and methods of use
AT500144A1 (de) * 2004-03-05 2005-11-15 Sanochemia Pharmazeutika Ag Tolperison enthaltende, pharmazeutische zubereitung mit steuerbarer wirkstofffreisetzung zur oralen verabreichung
KR20050104152A (ko) * 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
JP2007535545A (ja) * 2004-04-28 2007-12-06 プロキャリア・インコーポレーテッド 難吸収性薬剤の経口投与のための製剤
EP1765336A4 (de) 2004-06-25 2010-03-10 Univ Johns Hopkins Angiogenesehemmer
FR2878159B1 (fr) * 2004-11-24 2008-10-17 Flamel Technologies Sa Medicament oral a liberation modifiee d'au moins un principe actif sous forme multimicrocapsulaire
RU2401125C2 (ru) 2004-12-27 2010-10-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способ стабилизации лекарственного средства против деменции
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
WO2007016361A2 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
CA2617150C (en) * 2005-07-29 2016-06-14 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Use of chk2 kinase inhibitors for cancer treatment
US20070154413A1 (en) * 2005-12-30 2007-07-05 Nolan Lee Phillips Dentifrices comprising biogenic silica materials
US20070154412A1 (en) * 2005-12-30 2007-07-05 Nolan Lee Phillips Dentifrices comprising biogenic silica materials
TW200808380A (en) * 2006-02-21 2008-02-16 Shinetsu Chemical Co Enteric-coated preparation for site-specific delivery of drug to site within the small intestine
TR200807066T1 (tr) 2006-03-17 2009-11-23 Johns Hopkins University School Of Medicine Fizyolojik açıdan kullanışlı nıtroksıl donorleri olarak yeni n-htdroksilsülfonamid türevleri
KR20090034385A (ko) * 2006-07-19 2009-04-07 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 염증성 장질환을 치료하기 위한 5-아미노살리실산 함유 약제 및 인지질의 제제
US20080159968A1 (en) * 2006-12-27 2008-07-03 Fultz William C Dentifrices comprising biogenic silica materials and calcium carbonate
US20080159967A1 (en) * 2006-12-27 2008-07-03 Fultz William C Dentifrices comprising biogenic silica materials and at least one calcium phosphate
JP2010516680A (ja) 2007-01-19 2010-05-20 エックスカバリー，インコーポレイテッド キナーゼ阻害薬化合物
SG10201602375PA (en) 2007-09-26 2016-05-30 Univ Johns Hopkins N-Hydroxylsulfonamide Derivatives As New Physiologically Useful Nitroxyl Donors
CN102076342B (zh) 2008-05-07 2015-06-10 卡尔迪奥克斯尔制药公司 作为硝酰基供体的新亚硝基化合物及其使用方法
KR101691640B1 (ko) 2008-06-19 2016-12-30 엑스커버리 홀딩 컴퍼니 엘엘씨 키나아제 억제제 화합물로서의 치환된 피리다진 카르복사마이드 화합물
ES2641471T3 (es) 2008-10-06 2017-11-10 The Johns Hopkins University Compuestos de quinolina como inhibidores de la angiogénesis, metionina aminopeptidasa humana, y SirT1, y procedimientos de tratamiento de trastornos
EP2255794A1 (de) 2009-05-29 2010-12-01 H e x a l Aktiengesellschaft Magensaftresistenter Überzug
CN102470112A (zh) * 2009-07-30 2012-05-23 赢创罗姆有限公司 包含阴离子聚合物材料和含6-22个碳原子的饱和单羧酸的盐的组合物
US20110160200A1 (en) * 2009-11-23 2011-06-30 Cardioxyl Pharmaceuticals, Inc. Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
CA2782248A1 (en) * 2009-12-07 2011-06-16 Cardioxyl Pharmaceuticals, Inc. Bis-acylated hydroxylamine derivatives
CN102753520B (zh) * 2009-12-07 2016-06-08 约翰斯霍普金斯大学 N-酰氧基磺酰胺和n-羟基-n-酰基磺酰胺衍生物
EP2568973A2 (de) 2010-05-11 2013-03-20 Sensient Colors LLC Folienbeschichtungszusammensetzung und verfahren zu deren herstellung und verwendung
AU2011311814B2 (en) 2010-10-08 2016-12-22 Xcovery Holdings, Inc. Substituted pyridazine carboxamide compounds
JP2014504633A (ja) 2011-02-03 2014-02-24 ルピン・リミテッド 経口投与用放出制御医薬組成物
SG11201401587QA (en) 2011-10-17 2014-07-30 Univ Johns Hopkins Meldrum 's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors
BRPI1106900A2 (pt) * 2011-12-26 2013-11-05 Ems Sa Composição farmacêutica sólida compreendendo antibótico da familia das quinolonas e processo de sua obtenção
EP2830599B1 (de) 2012-03-29 2018-08-15 Therabiome, Llc Ortsspezifische gastrointestinale orale impfrezepte zur wirkung am ileum und am blinddarm
EP2841058A1 (de) * 2012-04-23 2015-03-04 Cadila Healthcare Limited Verzögert freigesetzte pharmazeutische zusammensetzungen aus salsalat
WO2014070919A1 (en) 2012-11-01 2014-05-08 The Johns Hopkins University Controlled hno release through intramolecular cyclization-elimination
EP3567031A1 (de) 2013-01-18 2019-11-13 Cardioxyl Pharmaceuticals, Inc. Nitroxyldonatoren mit verbessertem therapeutischem index
CN105120847B (zh) 2013-03-14 2018-12-28 塞拉拜姆有限责任公司 益生生物和/或治疗剂的靶向胃肠道递送
WO2014168874A2 (en) 2013-04-07 2014-10-16 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CN106456724A (zh) 2013-12-20 2017-02-22 博德研究所 使用新抗原疫苗的联合疗法
WO2015109210A1 (en) 2014-01-17 2015-07-23 Cardioxyl Pharmaceuticals, Inc. N-hydroxymethanesulfonamide nitroxyl donors
FR3018689B1 (fr) * 2014-03-20 2017-04-28 Centre Hospitalier Univ De Clermont Ferrand Inhibiteurs de l'acetylcholinesterase d'action centrale pour la prevention et/ou le traitement des neuropathies chimio-induites et leurs symptomes, compositions, utilisations, methodes et trousse correspondantes.
EP3148983A1 (de) 2014-05-27 2017-04-05 The Johns Hopkins University N-hydroxylaminobarbitursäure-derivate als nitroxyldonatoren
WO2015183839A1 (en) 2014-05-27 2015-12-03 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
JP2018506514A (ja) 2014-12-23 2018-03-08 セレコー，インコーポレイテッド 化合物、組成物および方法
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
TWI806815B (zh) 2015-05-20 2023-07-01 美商博德研究所有限公司 共有之ｇａｔａ３相關之腫瘤特異性新抗原
KR20180038440A (ko) 2015-06-09 2018-04-16 렉산 파마슈티컬스, 인코포레이티드 플루오로사이클로펜테닐시토신 용도 및 제조 방법
KR20180049015A (ko) 2015-09-04 2018-05-10 렉산 파마슈티컬스, 인코포레이티드 퀴녹살리닐-피페라진아미드의 사용 방법
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10738060B2 (en) 2016-10-03 2020-08-11 TLL Pharmaceutical, LLC JAK1 selective inhibitors and uses thereof
EP3574116A1 (de) 2017-01-24 2019-12-04 The Broad Institute, Inc. Zusammensetzungen und verfahren zum nachweis einer mutanten variante eines polynukleotids
EP3488868B1 (de) * 2017-11-23 2023-09-13 medac Gesellschaft für klinische Spezialpräparate mbH Pharmazeutische zusammensetzung zur oralen verabreichung enthaltend sulfasalazin oder ein organisches sulfasalazinsalz, herstellungsverfahren und verwendung
EP3489222A1 (de) 2017-11-23 2019-05-29 medac Gesellschaft für klinische Spezialpräparate mbH Sulfasalazinesalze, herstellungsverfahren und verwendungen
KR20210006353A (ko) 2018-05-04 2021-01-18 톨리스 상피 세포 및 골수 세포 모두를 활성화시키는 tlr3 리간드
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
WO2020215037A1 (en) 2019-04-18 2020-10-22 The Regents Of The University Of Michigan Combination with checkpoint inhibitors to treat cancer
EP4081195A1 (de) 2019-12-27 2022-11-02 Evelo Biosciences, Inc. Feste dosierungsformen, die bakterien und mikrobielle extrazelluläre vesikel enthalten
TW202140051A (zh) 2020-01-17 2021-11-01 美商艾弗洛生物科技股份有限公司 具有改善的崩散譜之固體劑型
EP4135670A1 (de) 2020-04-17 2023-02-22 Evelo Biosciences, Inc. Feste darreichungsformen mit verbesserten zerfallsprofilen
AU2021280261A1 (en) 2020-05-26 2023-01-19 Dionis Therapeutics, Inc. Nucleic acid artificial mini-proteome libraries
US20240050415A1 (en) 2020-06-05 2024-02-15 Henry Ford Health System Daclatasvir for use in treating lung and prostate cancer
CA3192766A1 (en) 2020-09-18 2022-03-24 Syed Altaf Solid dosage forms of bacteria
WO2022061123A1 (en) 2020-09-21 2022-03-24 Evelo Biosciences, Inc. Solid dosage forms with improved disintegration profiles
KR20230127985A (ko) 2020-10-29 2023-09-01 에벨로 바이오사이언시즈, 인크. 스피룰리나 성분을 포함하는 조성물
WO2022132738A1 (en) 2020-12-14 2022-06-23 Evelo Biosciences, Inc. Extracellular vesicle preparations
KR20230155422A (ko) 2020-12-22 2023-11-10 메카니스틱 테라퓨틱스 엘엘씨 Egfr 및/또는 pi3k 억제제로서의 치환된 아미노벤질헤테로아릴 화합물
WO2022140396A1 (en) 2020-12-22 2022-06-30 Evelo Biosciences, Inc. Compositions comprising animal hemoglobin
EP4284400A1 (de) 2021-01-26 2023-12-06 Evelo Biosciences, Inc. Prevotella extrazelluläre vesikelzubereitungen
WO2022182707A1 (en) 2021-02-26 2022-09-01 Evelo Biosciences, Inc. Compositions and methods for reducing cytokine expression
TW202302125A (zh) 2021-03-05 2023-01-16 美商艾弗洛生物科技股份有限公司 固體劑型
WO2022189861A1 (en) 2021-03-08 2022-09-15 Tollys Carbohydrate conjugates of tlr3 ligands and uses thereof
KR20240006543A (ko) 2021-04-08 2024-01-15 에벨로 바이오사이언시즈, 인크. 박테리아를 함유하는 약학적 조성물
WO2022221183A1 (en) 2021-04-12 2022-10-20 Evelo Biosciences, Inc. Fournierella extracellular vesicle preparations
WO2022251166A2 (en) 2021-05-25 2022-12-01 Evelo Biosciences, Inc. Bacterial compositions comprising soy hemoglobin
EP4385510A1 (de) 2021-08-10 2024-06-19 Betta Pharmaceuticals Co., Ltd Verwendung von ensartinib oder einem salz davon bei der behandlung von krankheiten mit exon-skipping-mutation von met 14
WO2023049268A1 (en) 2021-09-24 2023-03-30 Evelo Biosciences, Inc. Solid dosage forms containing bacteria and microbial extracellular vesicles
WO2023076733A1 (en) 2021-11-01 2023-05-04 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries
WO2023114293A1 (en) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Extracellular vesicle assays
WO2023114295A1 (en) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Veillonella parvula bacteria extracellular vesicle preparations
WO2023114300A1 (en) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Fournierella massiliensis bacteria extracellular vesicle preparations
WO2023146843A1 (en) 2022-01-25 2023-08-03 Evelo Biosciences, Inc. Extracellular vesicle compositions and methods of use
WO2023183396A1 (en) 2022-03-22 2023-09-28 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
WO2023200837A1 (en) 2022-04-13 2023-10-19 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
WO2023239728A1 (en) 2022-06-07 2023-12-14 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola extracellular vesicles
WO2024102226A1 (en) 2022-10-14 2024-05-16 Evelo Biosciences, Inc. Methods for assaying drug substances and drug products by using cell lines with nf-kb- inducible reporter genes

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2921883A (en) * 1957-05-03 1960-01-19 Smith Kline French Lab Novel coating material for medicaments
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
WO1981002671A1 (en) 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
DE3264867D1 (en) * 1981-04-27 1985-08-29 Haessle Ab New pharmaceutical preparation
ZA825384B (en) 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4755387A (en) 1985-03-21 1988-07-05 The Procter & Gamble Company Therapeutic particles
ES2062527T3 (es) 1989-05-11 1994-12-16 Chugai Pharmaceutical Co Ltd Preparacion oral que puede ser liberada en una region apropiada del intestino.
IE61651B1 (en) * 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
JPH06256166A (ja) 1993-01-06 1994-09-13 ▲寛▼治 ▲高▼田 薬物放出制御製剤
JPH072650A (ja) * 1993-06-18 1995-01-06 Tanabe Seiyaku Co Ltd 放出部位制御型製剤
JP2917799B2 (ja) * 1994-03-11 1999-07-12 田辺製薬株式会社 消化管内適所放出型製剤
JPH08143476A (ja) 1994-11-18 1996-06-04 Japan Tobacco Inc 薬物放出制御膜及び固形製剤
JPH10120571A (ja) 1996-10-22 1998-05-12 Sato Yakuhin Kogyo Kk 塩酸ジルチアゼム徐放性製剤
JP3047325B2 (ja) 1997-01-07 2000-05-29 謙二 徳永 品質劣化を抑制したローヤルゼリー錠剤の製造方法

Also Published As

Publication number Publication date
EP1101490B1 (de) 2005-04-13
AU4800999A (en) 2000-02-21
CA2338780A1 (en) 2000-02-10
EP1101490A1 (de) 2001-05-23
CN1163223C (zh) 2004-08-25
CA2338780C (en) 2007-01-02
KR20010074757A (ko) 2001-08-09
EP1101490A4 (de) 2002-04-03
DE69924735T2 (de) 2006-01-19
CN1311667A (zh) 2001-09-05
WO2000006128A1 (fr) 2000-02-10
KR100501022B1 (ko) 2005-07-18
ATE292961T1 (de) 2005-04-15
US6638534B1 (en) 2003-10-28

Similar Documents

Publication Publication Date Title
DE69924735D1 (de) Zur wirkstoffabgabe an zielorten im darm fähige zubereitung
DE69915184D1 (de) Pharmazeutische Formulierung und Dosierform bestehend aus Polysacchariden zur kontrollierten Wirkstoff-Freisetzung im Dickdarm
ATE343969T1 (de) Beschichtete medizinische geräte
BR9914384A (pt) Dispositivo e método para liberação de um agente ativo em aerossol aos pulmões de um paciente humano
DE3778223D1 (de) Biologisch erodierbares system mit gesteuerter freisetzung des arzneiwirkstoffes.
ATE344063T1 (de) Beschichtete medizinische geräte
NZ235807A (en) Controlled release pellet formulation (core coated with or comprising a glucocorticosteroid, and a polymeric outer coating); capsules containing pellets; and use in treating bowel disease
ATE285228T1 (de) Arzneistoffverabreichungsystem zur verzögerten, völlstandigen wirkstoffabgabe im verdauungstrakt
JP2003503153A5 (de)
BRPI9908893B8 (pt) composição polimérica líquida para a liberação controlada de substâncias bioativas hidrofóbicas.
ATE225165T1 (de) Im unteren teil des verdauungstrakts freisetzende pharmazeutische zubereitung in form einer beschichteten kapsel
ATE496642T1 (de) Vaskuläre biologisch abbaubare vorrichtung enthaltend einen ph-puffer
GEP20053427B (en) Pharmaceutical Compositions Providing Enhanced Drug Concentrations
PT1083879E (pt) Metodos e dispositivos para proporcionar uma terapia de drogas prolongada
WO2003077972A8 (en) Implantable drug delivery system
DK1133269T3 (da) Kontrolleret afgivelsesindretning til indgift af terapeutika i det indre öre
BR0117180A (pt) Forma de dosagem farmacêutica com múltiplos revestimentos
DE60112777D1 (de) Beschichtete medizinische geräte und verfahren zur sterilisation
PT96921B (pt) Dispositivo de libertacao intermitente
ES2053528T3 (es) Composicion farmaceutica que comprende un medicamento y un polimero hinchable en agua.
BRPI0418065A (pt) associação farmacêutica, uso da associação farmacêutica composição farmacêutica homogênea e método para o tratamento de doenças infecciosas mistas no aparelho reprodutivo humano
BR0202759A (pt) Composição farmacêutica de liberação modificada contendo bupropiona como substância ativa
BR9809552A (pt) Dispositivo transuretral para distribuição de um medicamento para a uretra de um corpo humano ou animal, processo para incorporar um medicamento em um dispositivo transuretral, e, utilização de um dispositivo transuretal.
IT1244037B (it) Forma farmaceutica a rilascio selettivo nel colon
DE3688355D1 (de) Fester koerper mit ueberzogenem kern.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition